Jill J.J. Geenen
The Netherlands Cancer Institute(NL)Oncode Institute(NL)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, Renal cell carcinoma treatment, PARP inhibition in cancer therapy, Advanced Breast Cancer Therapies, DNA Repair Mechanisms
Most-Cited Works
- → Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study(2019)550 cited
- → Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer(2017)145 cited
- → PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer(2017)132 cited
- → A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.(2018)63 cited
- → WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study(2023)43 cited
- → Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.(2019)22 cited
- → A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer(2021)4 cited
- → A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.(2019)3 cited
- A large lump in the left breast.(2014)
- → Adavosertib in combination with carboplatin in advanced TP53-mutated platinum-resistant ovarian cancer.(2022)1 cited